HER2-positive cancers can be treated with targeted therapies designed to inhibit the HER2 protein. Trastuzumab (Herceptin) is a monoclonal antibody that binds to the HER2 protein, blocking its signaling and marking cancer cells for destruction by the immune system. Other drugs like lapatinib and pertuzumab also target HER2 and are used in combination therapies to improve outcomes. Recently, antibody-drug conjugates (ADCs) like ado-trastuzumab emtansine (T-DM1) have been developed, combining targeted antibody therapy with chemotherapy.
